低风险子宫内膜癌患者卵巢保留的趋势与临床预测因素
基于美国国家癌症数据库的回顾性队列研究纳入2004年1月1日至2021年12月31日诊断为IA期1级或2级子宫内膜样癌的45岁以下女性共4343例,卵巢保留率从2004年16.7%降至2021年3.7%(平均年度百分比变化-8.6%,95%CI -10.4%至6.6%,P<.0001)。年龄较大、2级疾病及学术/研究机构治疗与较低的卵巢保留几率相关,种族/民族、保险、收入、城乡居住及诊断机构距离无显著相关。
要点
- 2004至2021年间,低风险子宫内膜癌45岁以下患者卵巢保留率由16.7%降至3.7%(平均年度百分比变化-8.6%,95%CI -10.4%至6.6%,P<.0001)。
- 多因素分析中,年龄较大(OR 0.94,95%CI 0.92-0.96)、2级疾病(OR 0.47,95%CI 0.34-0.63)及学术/研究机构治疗(OR 0.74,95%CI 0.60-0.91)与较低的卵巢保留几率相关。
- 在行淋巴结评估的患者中,卵巢保留率从2004年5.6%降至2021年2.8%(平均年度百分比变化-4.8%,95%CI -8.9%至0.62%,P=.03),亚裔/美洲印第安种族/民族与较高卵巢保留几率相关(OR 3.43,95%CI 1.97-6.04)。
核心结论
- 尽管有指南支持和强调长期健康获益的证据,卵巢保留在低风险子宫内膜癌绝经前患者中仍使用不足。
- 年龄较大、肿瘤分级较高及在学术中心治疗影响实践,凸显了错失循证、以患者为中心照护的机会。
- 需进一步研究以更好理解这些模式的驱动因素并支持更一致、个体化的手术决策。
研究设计与样本
- 回顾性队列研究,使用美国国家癌症数据库,纳入2004年1月1日至2021年12月31日诊断为IA期1级或2级子宫内膜样癌的45岁以下女性,共4343例。
- 对同时接受淋巴结评估的患者(作为术前肿瘤学规划的代理)进行亚组分析。
- 采用Cochran-Armitage趋势检验评估时间趋势,泊松模型估计平均年度百分比变化,卡方或Fisher精确检验评估组间差异,逻辑回归评估卵巢保留与临床及社会人口学变量的关联。
主要发现
- 2004年至2021年间,卵巢保留率从16.7%降至3.7%(平均年度百分比变化-8.6%,95%CI -10.4%至6.6%,P<.0001)。
- 多因素逻辑回归中,年龄较大(OR 0.94,95%CI 0.92-0.96,P<.001)、2级疾病(OR 0.47,95%CI 0.34-0.63,P<.0001)及学术/研究机构治疗(OR 0.74,95%CI 0.60-0.91,P=.006)与较低的卵巢保留几率相关。
- 种族/民族、保险状态、收入、城乡居住及诊断机构距离与卵巢保留无显著相关。
- 在行淋巴结评估的患者中,卵巢保留率从2004年5.6%降至2021年2.8%(平均年度百分比变化-4.8%,95%CI -8.9%至0.62%,P=.03)。
- 在该队列中,诊断时年龄较大(OR 0.92,95%CI 0.89-0.96,P<.001)与卵巢保留几率降低相关,亚裔/美洲印第安种族/民族(OR 3.43,95%CI 1.97-6.04,P<.001)与卵巢保留几率升高相关。
局限性
- 需进一步研究以更好理解这些模式的驱动因素并支持更一致、个体化的手术决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: For premenopausal patients with early-stage endometrial cancer, iatrogenic menopause raises concerns regarding cardiovascular risk, cognitive decline, and loss of future fertility. Although previous studies have demonstrated the safety of ovarian preservation in selected patients with low-risk endometrial cancer, and national guidelines support its use in selected cases, contemporary ovarian preservation practices and potential sociodemographic disparities in care delivery remain poorly characterized. This study aimed to assess national trends in ovarian preservation and identify clinical and sociodemographic factors associated with ovarian preservation among premenopausal women. STUDY DESIGN: We conducted a retrospective cohort study using the National Cancer Database, including women aged less than 45 years diagnosed with stage IA, grade 1 or 2 endometrioid endometrial cancer between January 1, 2004 and December 31, 2021. A subanalysis was performed among patients who also underwent lymph node assessment as proxy for patients with preoperative oncologic planning. Time trends were evaluated using the Cochran-Armitage trend test, and average annual percent change was estimated using a Poisson model. Group differences were assessed using Chi-squared or Fisher's exact tests, and logistic regression was used to evaluate associations between ovarian preservation and clinical and sociodemographic variables. RESULTS: A total of 4343 women met the inclusion criteria. Between 2004 and 2021, ovarian preservation rates declined from 16.7% to 3.7% (average annual percent change, -8.6%; 95% confidence interval, -10.4% to 6.6%; P<.0001). On multivariable logistic regression analysis, older age (odds ratio, 0.94; 95% confidence interval, 0.92-0.96; P<.001), grade 2 disease (odds ratio, 0.47; 95% confidence interval, 0.34-0.63; P<.0001), and treatment at academic/research facilities (odds ratio, 0.74; 95% confidence interval, 0.60-0.91; P=.006) were associated with lower odds of ovarian preservation. Race/ethnicity, insurance status, income, urban/rural residence, and distance to the diagnosing facility were not significantly associated with ovarian preservation. Among patients who underwent lymph node assessment, ovarian preservation similarly declined, from 5.6% in 2004 to 2.8% in 2021 (average annual percent change, -4.8%; 95% confidence interval, -8.9% to 0.62%; P=.03). In this cohort, older age at diagnosis (odds ratio, 0.92; 95% confidence interval, 0.89-0.96; P<.001) was associated with decreased odds of ovarian preservation and Asian/American Indian race/ethnicity (odds ratio, 3.43; 95% confidence interval, 1.97-6.04; P<.001) were associated with higher odds of ovarian preservation. CONCLUSION: Ovarian preservation remains underused in premenopausal patients with low-risk endometrial cancer despite guideline support and evidence highlighting its long-term health benefits. Older age, higher tumor grade, and treatment at academic centers influence practice, highlighting missed opportunities for evidence-based, patient-centered care. Further research is needed to better understand the drivers of these patterns and support more consistent, individualized surgical decision-making.
引用
- Kanbergs A, Agusti N, Perkins G, et al. Trends and clinical predictors in ovarian preservation in patients with low-risk endometrial cancer. Am J Obstet Gynecol. 2025. PMID: 41223960. doi:10.1016/j.ajog.2025.10.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。